<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Abbas A</submitter><funding>British Heart Foundation</funding><funding>Medical Research Council</funding><funding>Wellcome Trust</funding><pagination>2169-78</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3142083</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>60(8)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>In mice, haploinsufficiency of the IGF-1 receptor (IGF-1R(+/-)), at a whole-body level, increases resistance to inflammation and oxidative stress, but the underlying mechanisms are unclear. We hypothesized that by forming insulin-resistant heterodimers composed of one IGF-1Rαβ and one insulin receptor (IR), IRαβ complex in endothelial cells (ECs), IGF-1R reduces free IR, which reduces EC insulin sensitivity and generation of the antioxidant/anti-inflammatory signaling radical nitric oxide (NO).&lt;h4>Research design and methods&lt;/h4>Using a number of complementary gene-modified mice with reduced IGF-1R at a whole-body level and specifically in EC, and complementary studies in EC in vitro, we examined the effect of changing IGF-1R/IR stoichiometry on EC insulin sensitivity and</pubmed_abstract><journal>Diabetes</journal><pubmed_title>The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium.</pubmed_title><pmcid>PMC3142083</pmcid><funding_grant_id>PG/09/042/27518</funding_grant_id><funding_grant_id>RG/07/003/23133</funding_grant_id><funding_grant_id>FS/10/028/28252</funding_grant_id><funding_grant_id>090532</funding_grant_id><pubmed_authors>Beech DJ</pubmed_authors><pubmed_authors>Viswambharan H</pubmed_authors><pubmed_authors>Kearney MT</pubmed_authors><pubmed_authors>Gage M</pubmed_authors><pubmed_authors>Kahn M</pubmed_authors><pubmed_authors>Sukumar P</pubmed_authors><pubmed_authors>Imrie H</pubmed_authors><pubmed_authors>Rajwani A</pubmed_authors><pubmed_authors>Smith J</pubmed_authors><pubmed_authors>Channon KM</pubmed_authors><pubmed_authors>Wheatcroft SB</pubmed_authors><pubmed_authors>Cubbon RM</pubmed_authors><pubmed_authors>Xuan S</pubmed_authors><pubmed_authors>Abbas A</pubmed_authors><pubmed_authors>Galloway S</pubmed_authors><pubmed_authors>Yuldeshava N</pubmed_authors><pubmed_authors>Grant PJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium.</name><description>&lt;h4>Objective&lt;/h4>In mice, haploinsufficiency of the IGF-1 receptor (IGF-1R(+/-)), at a whole-body level, increases resistance to inflammation and oxidative stress, but the underlying mechanisms are unclear. We hypothesized that by forming insulin-resistant heterodimers composed of one IGF-1Rαβ and one insulin receptor (IR), IRαβ complex in endothelial cells (ECs), IGF-1R reduces free IR, which reduces EC insulin sensitivity and generation of the antioxidant/anti-inflammatory signaling radical nitric oxide (NO).&lt;h4>Research design and methods&lt;/h4>Using a number of complementary gene-modified mice with reduced IGF-1R at a whole-body level and specifically in EC, and complementary studies in EC in vitro, we examined the effect of changing IGF-1R/IR stoichiometry on EC insulin sensitivity and</description><dates><release>2011-01-01T00:00:00Z</release><publication>2011 Aug</publication><modification>2025-04-04T12:00:43.518Z</modification><creation>2019-03-27T03:07:20Z</creation></dates><accession>S-EPMC3142083</accession><cross_references><pubmed>21677284</pubmed><doi>10.2337/db11-0197</doi></cross_references></HashMap>